Voorbeelden van het gebruik van Sofosbuvir in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Weeks SMV+ sofosbuvir.
Daklinza+ sofosbuvir+ ribavirin for 12 weeks or.
Or 12 weeks SMV+ sofosbuvir.
Median sofosbuvir EC50, nM range.
Weeks simeprevir+ sofosbuvir.
Mensen vertalen ook
Daklinza+ sofosbuvir(without ribavirin) for 24 weeks.
Use with ledipasvir and sofosbuvir.
Sofosbuvir has been authorised as Sovaldi since January 2014.
OLYSIO in combination with sofosbuvir.
Sofosbuvir is a nucleotide prodrug that is extensively metabolised.
Daklinza in combination with sofosbuvir.
In vitro potential for sofosbuvir/velpatasvir drug-drug interations.
Simeprevir in combination with sofosbuvir.
Sofosbuvir and GS-331007 AUCs are near dose-proportional over the dose range of 200 mg to 1,200 mg.
Daclatasvir in combination with sofosbuvir.
Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 400 mg.
Interaction only studied with sofosbuvir.
Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects
It is a combination of sofosbuvir and velpatasvir.
The predominant circulating metabolite of sofosbuvir.
The SVR12 rate in the sofosbuvir+ ribavirin treatment group was statistically significant when compared to placebo p< 0.001.
The active substances are ledipasvir and sofosbuvir.
The sofosbuvir resistance-associated substitution S282T in NS5B was not detected in any virologic failure isolate from the Phase 3 studies.
See also under Use with ledipasvir and sofosbuvir below.
Relative to healthy subjects(n 284), the sofosbuvir and GS-331007 AUC0-24 was 57% higher
All of these patients received Daklinza+ sofosbuvir+ ribavirin.
high fat meal increased sofosbuvir AUC0-inf by 60% and 78%, respectively, but did not substantially affect the sofosbuvir Cmax.
Harvoni contains the active substances ledipasvir and sofosbuvir.
velpatasvir, and sofosbuvir concentrations unknown.
The sofosbuvir resistance-associated substitution S282T was not detected in the baseline NS5B sequence of any patient in Phase 3 studies by population